• Fay J Hlubocky, Kimberly Webster, Jennifer Beaumont, John Cashy, Diane Paul, Amy Abernethy, Karen L Syrjala, Jamie Von Roenn, and David Cella.
• Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Northwestern Medical Faculty Foundation, Evanston, IL, USA. fhlubock@medicine.bsd.uchicago.edu
• Leuk. Lymphoma. 2013 Sep 1; 54 (9): 1942-6.

AbstractDespite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.

17 keywords...

hide…